Product Description
A heparin derivative in which the 2-O and 3-O sulfate groups of heparin are removed and that lacks anticoagulant activity, with potential anti-inflammatory, immodulatory and antineoplastic activities. Upon administration, dociparstat sodium binds to both chemokine stromal cell-derived factor 1 (SDF-1 or CXCL12) and CXC chemokine receptor 4 (CXCR4). This prevents the interaction of CXCL12 with CXCR4, blocks CXCR4 activation, and may result in decreased proliferation and migration in CXCR4-overexpressing tumor cells. In addition, inhibition of CXCL12/CXCR4 interaction may induce mobilization of hematopoietic cells from the bone marrow into the blood. In addition, dociparstat sodium prevents the interaction of the receptor for advanced glycation end-products (RAGE) with its ligands, including advanced glycation end-products (AGEs), Mac-1(CD11b/CD18), the nuclear pro-inflammatory protein high mobility group box protein-1 (HMGB-1), carboxymethyl lysine-bovine serum albumin (CML-BSA) and members of the S100 calgranulin family. In addition, this agent inhibits the enzymes heparanase, cathepsin G, and human leukocyte elastase, which are involved in inflammation and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/dociparstat-sodium)
Mechanisms of Action: CXCR4 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jazz
Company Location: Europe
Company CEO: Bruce C. Cozadd
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Severe Acute Respiratory Syndrome|Acute Myeloid Leukemia|Acute Lung Injury|COVID-19|Respiratory Insufficiency
Phase 2: Chronic Obstructive Pulmonary Disease|Acute Myeloid Leukemia
Phase 1: Preleukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02995655 |
CNTX-CX-01-2016-MDS-1 | P1 |
Completed |
Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome |
2018-09-13 |
12% |
2019-12-08 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT02873338 |
CNTX-CX-01-2015-AML-1 | P2 |
Completed |
Acute Myeloid Leukemia |
2019-06-01 |
49% |
2024-11-27 |
Primary Endpoints |
NCT00457951 |
COPD | P2 |
Terminated |
Chronic Obstructive Pulmonary Disease |
2009-08-01 |
2021-11-06 |
Primary Endpoints|Treatments |
|
2006-006378-32 |
2006-006378-32 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-06-03 |
2022-03-12 |
Treatments |
|
NCT04571645 |
AML | P3 |
Terminated |
Acute Myeloid Leukemia |
2022-05-16 |
9% |
2024-04-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04389840 |
CMX-DS-004 | P3 |
Terminated |
Acute Lung Injury|Severe Acute Respiratory Syndrome|COVID-19|Respiratory Insufficiency |
2021-05-20 |
14% |
2022-08-31 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/21/2025 |
News Article |
TOMY Company to Hold BEYBLADE X WORLD CHAMPIONSHIP 2025 on October 11 and 12, 2025 |
|
05/12/2022 |
News Article |
Chimerix to Participate in Maxim Group Panel Discussion |
|
05/09/2022 |
News Article |
Chimerix to Report First Quarter 2022 Financial Results and Provide an Operational Update on May 16, 2022 |
|
03/21/2022 |
News Article |
Chimerix to Present at Maxim Group 2022 Virtual Growth Conference |
|
03/10/2022 |
PubMed |
Genetic and Pathogenic Characterisation of a Virulent Akabane Virus Isolated from Goats in Yunnan, China. |
|
01/08/2022 |
PubMed |
HMGB1 Inhibition to Ameliorate Organ Failure and Increase Survival in Trauma. |
|
11/01/2021 |
PubMed |
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. |